Raised Intracranial Pressure After Trauma: Characterisation And Development Of Pharmacological Interventions
Funder
National Health and Medical Research Council
Funding Amount
$589,788.00
Summary
Raised intracranial pressure (ICP) commonly occurs after traumatic brain injury (TBI) and is thought to be responsible for up to 50% of all mortality, as well as significantly contributing to the persistent neurological deficits in survivors. Few studies have examined the dynamics of raised ICP after TBI, or its effects on brain oxygenation. This study will fully characterize changes in ICP and brain oxygen after TBI and develop novel treatments to control such changes.
The Role Of Liver Fructose-1,6-phosphatase (FBPase) In Body Weight Regulation
Funder
National Health and Medical Research Council
Funding Amount
$494,718.00
Summary
We have shown that fructose-1,6-bisphosphatase (FBPase), an enzyme important in producing sugar from the liver and one that is connected to Type 2 diabetes, does not cause an increase in sugar production when there is more of the enzyme in mouse livers. It does, however, lower both body weight and the amount of food the mice consume. We therefore hypothesise that liver FBPase is important in controlling body weight in humans and our project aims to find out exactly how and why this happens.
The Role Of Neuropeptides In The Acute And Long-term Effects Of MDMA, Methamphetamine And GHB
Funder
National Health and Medical Research Council
Funding Amount
$472,321.00
Summary
The widespread use of 'party drugs' (ecstasy, methamphetmaine and GHB) is a major health issue in Australia. We propose a novel hypothesis that key acute and long-term effects of these drugs may involve an action on the neuropeptide oxytocin. A number of experiments are planned to test this hypothesis. The findings from this project will be used to better understand and to explore novel treatments for people who suffer problems as a result of using these drugs.
Preclinical Validation Of Oxytocin As A Novel Treatment For Alcohol Dependence
Funder
National Health and Medical Research Council
Funding Amount
$517,624.00
Summary
Alcohol dependence is a major cause of mental and physical illness in Australia. Current medications for treating this condition are of limited effectiveness. This project will investigate the ability of the hormone oxytocin to reduce alcohol abuse and alcohol craving and to reverse the brain damage that alcohol causes. The project will also develop new medications, based on oxytocin, but with more powerful and longer lasting effects. These medications may provide a breakthrough in the fight aga ....Alcohol dependence is a major cause of mental and physical illness in Australia. Current medications for treating this condition are of limited effectiveness. This project will investigate the ability of the hormone oxytocin to reduce alcohol abuse and alcohol craving and to reverse the brain damage that alcohol causes. The project will also develop new medications, based on oxytocin, but with more powerful and longer lasting effects. These medications may provide a breakthrough in the fight against alcoholism.Read moreRead less
Uncovering Oxytocin And Vasopressin Release And Functions With Novel Optical Tools
Funder
National Health and Medical Research Council
Funding Amount
$631,634.00
Summary
Oytocin and vasopressin are peptides in the brain that act as releasable neuromodulators and the balance of these peptides is implicated in the control of social behaviour and anxiety. We aim to investigate the release and function of these neuropeptides with 3 novel protein-based tools in a stressful learning paradigm and anxious behaviour. The understanding of their function will have important implications in the development of therapeutics for neurological conditions and drug addictions.
Narcolepsy With Cataplexy: A Brain Orexin Replacement Strategy
Funder
National Health and Medical Research Council
Funding Amount
$810,784.00
Summary
Narcolepsy with cataplexy is a debilitating, life-long sleep-wake disorder, caused by the irreversible loss of the brain peptide 'orexin'. There is no satisfactory and safe treatment. We aim to develop an orexin analogue, delivered directly to the brain of sheep (relevant in size and translatable to patients) by a programmable pump to timely activate the orexin 'wake-up' switch. This innovative precision medicine project will significantly improve the quality of life of narcolepsy patients.